AP-T: The only factors affecting the safety of patients with inflammatory bowel disease with Vidoju and Usta monotherapy are cogeneration, not patient age.

Inflammatory bowel disease (IBD), which includes Crohn's disease (CD) and ulcerative colitis (UC), is a chronic immunometric-mediated disease that mainly affects the gastrointestinal tract and is characterized by repeated changes in the recurrence and remission of the disease.
the presence of IBD increases the risk of complications, such as cardiovascular disease and diabetes.
years, patient age has become a potential risk factor for poor treatment outcomes in immunomodulants or biotherapy.
is more likely to be a more reliable predictive indicator of treatment outcomes than age itself, as its presence increases the risk of drug interactions, reduces compliance with treatment and has an effect.
Vedolizumab and ustekinumab both showed good safety in both the registration trial and observation queue, but it is not clear how the presence of the combination has affected the therapeutic effects of Vidojuumab and Usta monoantigen therapy in IBD patients.
, this study aims to assess the relationship between age and merging disorders and the safety and effectiveness of Vidoju monoantigen and usta monoantigen in IBD.
researchers looked at IBD patients who started using vedolizumab or ustekinumab in routine treatments.
used the Charson Merger Index (CCI) to assess the prevalence of the disease.
association between age and CCI, as well as effective results after 52 weeks of treatment (clinical remission and remission, corticosteroid-free remission, clinical remission combined with bio-chemical remission) were calculated.
the researchers included a total of 203 patients receiving Vidoju monoantigen and 207 IBD patients receiving Ustad monoantigen therapy, with an average age of 42.2 years and 41.6 years, respectively.
duration of the medium treatment was 54.0 months and 48.4 weeks, and the medium follow-up time was 104.0 weeks and 52.0 weeks.
in Vidoju monotherapy, CCI is independently associated with any form of infection (OR 1.387, 95% CI 1.022-1.883, P=0.036) and hospitalization (OR 1.586,95%CI 1.127-2.231, P=0.008).
in Ustha monoantigen, CCI was independently associated with hospitalization (OR 1.621,95% CI 1.034-2.541, P=0.035).
CCI has nothing to do with validity, age has nothing to do with any results.
, the researchers said, the IBD patient's own combined disease, rather than the patient's age, was associated with an increased risk of hospitalization and infection in both therapies.
IBD patients should do more to manage the disease in order to benefit more effectively from biologic treatment.
.